ANAB: AnaptysBio Inc Company Value to Net Income
Geopolitical instability and patent risks are creating supply chain challenges for AnaptysBio, Inc. (ANAB). The issuer's P/E history demonstrates structural imbalances in business valuation, where the 7.30 level reflects the current magnitude of the metric. Synergy with pharma behemoths is accelerating the search for new antibodies, while preparations for the commercialization of dermatitis drugs confirm the high medical significance of the company's developments.
%20P%2FE%20Multiple&width=1200&height=400&colorIndex=0&v=mwa76aez.ocr-7cpmfb4&start=20220704&end=20261110&filename=GURU_Markets_-_ANAB_-_AnaptysBio-Inc._-_PE-Multiple "ANAB: AnaptysBio, Inc. Business Payback Period 07/04/2022 - 11/10/2026 | 👁️GURU.Markets👁️")
Analytical breakdowns for AnaptysBio Corp (ANAB)
- price and consensus price forecast:
- market capitalization information:
- balance sheet net asset value indicators:
- debt and solvency information:
- earnings and market multiples details:
ANAB - Company Net Income|Net Profit Forecast AnaptysBio, Inc.|ANAB - P/E Multiple|Forward P/E Multiple AnaptysBio Inc|ANAB - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio AnaptysBio, Inc.|ANAB - Operating profit before deduction of amortization|Earnings per share for the last four quarters AnaptysBio|ANAB - Net earnings per share for the last 12 months|Earnings per share growth in annualized terms for the last twelve months anaptysbio.com|ANAB - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year AnaptysBio, Inc.
Comprehensive company analysis:anaptysbio.com ANAB
AnaptysBio, Inc. specializes in developing innovative antibodies for the therapy of severe inflammatory processes, leveraging its high authority in immunology. An analysis of the company's normalized P/E allows for a comparison of current market capitalization with actual earnings, determining the cost of each unit of profit and helping investors assess the premium paid for the future potential of the issuer's biopharmaceutical developments.
Key competitors
P/E Multiple argenx.com|Price to Earnings Ratio BNTX (BioNTech)|ABVX (ABIVAX) - Company Value to Net Income|P/E Multiple ADMA (ADMA Bio)|Business Payback Period Protagonist Corp (PTGX)|IMVT - Price to Earnings Ratio|kiniksa.com (KNSA) - Price to Earnings Ratio|Grifols (GRFS) - Price to Earnings Ratio|Price to Earnings Ratio Adaptive Biotech|Price to Earnings Ratio CLDX|P/E Multiple Aurinia Corp|Price to Earnings Ratio BioCryst (BCRX)|veratx.com - Price to Earnings Multiple|P/E Multiple DNTH (Dianthus Therapeutics, Inc.)|Pharvaris NV (PHVS) - Market Cap to Earnings|AbCellera Bio - P/E Multiple|TRML - P/E Multiple|Precigen, Inc. (PGEN) - Price to Earnings Ratio|Price to Earnings Multiple PHAR|NKTR (Nektar Therapeutics Inc.) - P/E Multiple|P/E Multiple Upstream Bio, Inc.|Price to Earnings Ratio Zenas Biopharma, Inc. (ZBIO)|IMNM: Market Cap to Net Income|Gossamer Bio, Inc. - Price to Earnings Ratio|Market Price to Net Income Ratio KALV (kalvista.com)|SEPN: Price to Earnings Ratio|Market Cap to Earnings Pieris Pharma|Savara Corp (SVRA) - Price to Earnings Ratio|RIGL - Business Payback Period|ATXS (Astria Therapeutics) - P/E Multiple|Price to Earnings Ratio ENGN|P/E Multiple RAPT|Business Payback Period aerovatetx.com|Price to Earnings Ratio Aclaris ACRS|Kyverna Therapeutics, Inc (KYTX) - Market Cap to Earnings|TLSA: Price to Earnings Ratio|Company Value to Net Income CABA (cabalettabio.com)|VTYX: P/E Multiple|THTX - Business Payback Period|Price to Earnings Ratio Avalo Therapeutics Inc.|Price to Earnings Multiple ELDN (Eledon Pharmaceuticals, Inc)|P/E Multiple AGEN|Price to Earnings Ratio climbbio.com CLYM|Zura Bio - Price to Earnings Ratio|Business Payback Period aTyr Pharma Inc (ATYR)|Adagene Corp - P/E Multiple|IMA - P/E Multiple|shattucklabs.com (STTK) - Price to Earnings Ratio|Price to Earnings Multiple EQ|CNTB (Connect Biopharma Holdings) - P/E Multiple|P/E Multiple Immunic Inc|P/E Multiple ATRA|Price to Earnings Ratio IFRX (inflarx.de)|Price to Earnings Ratio X4 Pharmaceuticals XFOR|ACET (Adicet Bio Inc.) - Market Cap to Net Income|Celularity Corp - P/E Multiple|Company Value to Net Income INMB (INmune Bio Inc)|BRNS: P/E Multiple|Kezar Life Sciences Inc (KZR) - P/E Multiple|Price to Earnings Ratio SAB Biotherapeutics|AKTX: Company Value to Net Income|Price to Earnings Ratio Enlivex Therapeutics (ENLV)|Price to Earnings Ratio q32bio.com QTTB|P/E Multiple GOVX (GeoVax Labs Inc)|P/E Multiple Edesa Biotech Corp EDSA|IBIO: Price to Earnings Ratio|Company Value to Net Income CARM (Carisma Therapeutics)|XTLB: P/E Multiple|BOLT - Business Payback Period|Price to Earnings Ratio HCW Biologics, Inc.|Price to Earnings Ratio Aptevo (APVO)|Price to Earnings Ratio AIM ImmunoTech Inc. (AIM)|Price to Earnings Ratio aditxt.com ADTX|GRI Bio - Price to Earnings Ratio|P/E Multiple XORTX Therapeutics Inc XRTX|HIND - Price to Earnings Ratio|REVB (Revelation Biosciences Corp) - Price to Earnings Multiple|INDP: P/E Multiple|Market Cap to Earnings scinai.com (SCNI)|CALI (CalciMedica Inc) - P/E Multiple|P/E Multiple Affimed Therapeutics|Price to Earnings Ratio Allakos Inc. (ALLK)|hookipapharma.com - Price to Earnings Multiple|P/E Multiple IGMS (IGM Biosciences)|P/E Multiple iteostherapeutics.com ITOS|OCEA - Price to Earnings Ratio|Market Cap to Net Income TCBP|THRD (Third Harmonic Bio, Inc) - Price to Earnings Ratio
